Objective To analyze the clinical manifestations, diagnosis and treatment measures of patients with coronavirus disease 2019 (COVID-19)-associated organizing pneumonia (OP), so as to improve the clinicians’ awareness and treatment of the disease. Methods The clinical data, diagnosis and treatment of 2 cases of COVID-19-associated OP from our hospital were summarized. Relevant case data were retrieved from the PubMed database, and the demographic characteristics, imaging manifestations, diagnosis and treatment process, and outcomes of patients with COVID-19-associated OP were summarized and analyzed. Results A total of 45 patients with COVID-19-associated OP were retrieved from PubMed database. A total of 47 patients were enrolled in the data analysis, and the age ranged from 25 to 84 (59.6±13.0) years old, with 35 (74.5%) males and 12 (25.5%) females. Thirty-one (66.0%) patients were diagnosed as severe or critical COVID-19, and 34 (72.3%) patients required respiratory support. The duration from initial diagnosis of COVID-19 to clinical diagnosis of OP was 12-68 (32.3±13.5) d. Twenty (42.6%) patients were initially cured and discharged or only observed at home, and then were diagnosed as OP due to recurrence of symptoms; 27 (57.4%) patients were hospitalized before diagnosis of OP. The computed tomography (CT) results of 44 (93.6%) patients showed multiple lesions in both lungs, and the main lesion patterns were consolidation (35 cases, 74.5%), ground glass opacity (31 cases, 66.0%), interlobular septal thickening (14 cases, 29.8%) and linear shadow (14 cases, 29.8%), and 28 (59.6%) cases of the lesions showed typical peripheral distribution. Forty-five (95.7%) patients were treated with glucocorticoids. All patients were clinically stable during the follow-up period. Conclusion COVID-19-associated OP may be related to the pulmonary sequelae of COVID-19 and persistent hypoxia in some severe patients. Chest CT plays an important role in the diagnosis of OP. Glucocorticoid therapy can achieve a good prognosis, but the optimal dose and course of treatment still need further clinical research.